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ABSTRACT 
 
The present investigation has been undertaken to study the anticonvulsant activity of 
chloroform root extract of Aconitum heterophyllum. The plant Aconitum heterophyllum 
of family Ranunculaceae is an Ayurvedic herb which is known for its significant medical 
properties. Experiments were conducted following standard procedures. The chloroform 
extract of Aconitum heterophyllum were evaluated for their invivo antioxidant and 
anticonvulsant properties and neurotransmitters level. The anticonvulsant activity of  
CEAH was evaluated using maximal electroshock induced convulsion and 
pentylenetetrazole induced convulsion models. Diphenylhydantoin was used as standard 
for MES and Sodium Valproate was used as standard for PTZ. Extracts treated groups 
showed higher in vivo antioxidant, and anticonvulsant activities. They also showed 
higher activity in neurotransmitters level. CEAH exhibited similar anticonvulsant 
activity that of the standard but with lesser magnitude. The result may be attributed to the 
chemical constituents such as diterpene alkaloids  present in it which may be due to their 
individual or cumulative effect that enhanced anticonvulsant activity and provided 
scientific evidence to the ethnomedicinal features of Aconitum heterophyllum. These 
findings could justify the inclusion of this plant in the management of epilepsy. 
Keywords: CEAH, anticonvulsant, chemical constituents.  
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1. INTRODUCTION 
 This chapter presents; the background of the study, statement of problem, 
definition of terms, theoretical basis, purpose of study, hypothesis, specific aims and plan 
of work. 
 
1.1 BACKGROUND OF THE STUDY 
Epilepsy is a chronic disorder of the brain that affects people worldwide. As per 
WHO, epilepsy is characterized by recurrent seizures, which are brief episodes of 
involuntary movement that may involve a part of the body (partial) or the entire body 
(generalized), and are sometimes accompanied by loss of consciousness and control of 
bowel or bladder function.[1] 
 Epilepsy was one of the first brain disorders to be described. It was mentioned in 
ancient Babylon more than 3,000 years ago. The strange behaviour caused by some 
seizures has contributed through the ages to many superstitions and prejudices. From 
greek word attack, the word epilepsy is derived. In earlier times, People once thought 
that those with epilepsy were being visited by demons or gods. However, in 400 B.C., 
the early physician Hippocrates suggested that epilepsy was a disorder of the brain, and 
we now know that he was right.
[2] 
Epilepsy is a major neurological disorder and upto 5% of the world population 
develops epilepsy in their lifetime. The current therapy of epilepsy with modern 
antiepileptic drugs is associated with side effects, dose-related and chronic toxicity as 
well as teratogenic effects and approximately 30% of the patients continue to have 
seizures with current antiepileptic drug therapy.
 
Traditional systems of medicines are popular in developing countries and upto 
80% of the population relies on traditional medicines/ folk remedies for their primary 
health care need. Hence, there is a need to discover an alternative agent from natural 
sources.
[3] 
 Aconitum heterophyllum used as a herbal medicine and is well known for its 
traditional uses such as expectorants, diuretics, laxative etc. Various studies shows that 
the active principle diterpene alkaloids having a crucial role in treatment of epilepsy.  
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Aconitum heterophyllum is rich in diterpene alkaloids. Since Aconitum heterophyllum 
have not been studied for its antiepileptic activity, the present study was aimed to 
evaluate the antiepileptic activity of chloroform extract of Aconitum heterophyllum. 
 
1.2 STATEMENT OF THE PROBLEM 
More than 2 million people in the United States have experienced an unprovoked 
seizure or been diagnosed with epilepsy. For about 80 percent of those diagnosed with 
epilepsy, seizures can be controlled with modern medicines and surgical techniques. 
However, about 25 to 30 % of people with epilepsy will continue to suffer from seizures 
with the current available treatment. Doctors call this situation intractable epilepsy. 
Having a seizure does not necessarily mean that a person has epilepsy. Only when a 
person has had two or more seizures is he or she considered to have epilepsy.
[2]
 
 Approximately 50 million people currently live with epilepsy worldwide. An 
estimate shows that people suffering from epilepsy(i.e. continuing seizures or with the 
need for treatment) at a given time is between 4 and 10 per 1000 people. However, some 
studies shows that the proportion is much higher in  low- and middle-income countries, 
between 7 and 14 per 1000 people.
 
 Globally, each year epilepsy was  diagnosed on  estimating 2.4 million people. In 
high-income countries, annual new cases are between 30 and 50 per 100 000 people in 
the general population. This figure can be up to two times higher in low- and middle-
income countries.
 
Various factors such as higher incidence of road traffic injuries, birth-related 
injuries, variations in medical infrastructure, availability of preventative health 
programmes and awareness among people can be the reason for these. Close to 80% of 
people with epilepsy live in low- and middle-income countries.
[1] 
 It is estimated that there are more than 10 million persons with epilepsy  in India. 
Its prevalence is about 1% in our population. The prevalence is higher in the rural (1.9%) 
compared to urban population (0.6%). In the Bangalore Urban Rural Neuro-
epidemiological Survey (BURNS), estimated that a prevalence rate of 8.8/1000 
population was observed, with the rate in rural communities (11.9) being twice that of  
urban areas (5.7).
[4]
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Epilepsy accounts for 0.6%, of the global burden of disease, a time-based 
measure that combines years of life lost due to premature mortality and time lived in less 
than full health. In terms of health care needs, premature death and lost work 
productivity, epilepsy has significant economic implications.  
An Indian study conducted in 1998 calculated that the cost per patient of epilepsy 
treatment was as high as 88.2% of the country’s per capita Gross National Product 
(GNP), and epilepsy-related costs, which included medical costs, travel, and lost work 
time, exceeded $2.6 billion/year (2013 USD).
[1]
 
 Estimates suggest that available medication controls the seizures in only 50% of 
patients or decreases the incidence in only 75% of patients. The search for agents with 
anticonvulsant activity with more selectivity and lower toxicity continues to be an area of 
investigation in future.
[4] 
 
1.3 DEFINITIONS 
 Epilepsy  
These are a group of CNS disorders  characterized by paroxysmal cerebral dysrhythmia, 
manifesting as brief episodes(seizures) of loss or disturbance of consciousness, with or 
without characteristic body movements(convulsions), sensory or psychiatric 
phenomena.
[5] 
 Seizures  
A seizure is a sudden surge of electrical activity in the brain. 
 Convulsion  
A convulsion is a condition in which body muscles contract and relax rapidly and 
repeatedly, results in an uncontrolled shaking of the body.
[6] 
 
1.4 THEORETICAL BASIS 
Despite the successful development of various new antiepileptic drugs (AEDs) in recent 
decades, the search for new therapies with better efficacy and tolerability remains an 
important goal. The discovery and development of a new AED relies heavily on the 
preclinical use of animal models to establish efficacy and safety prior to first trials in 
humans. This approach has been very successful and crucially contributed to the  
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development of numerous clinically effective AEDs. In the discovery and development 
of new AEDs, animal models of seizures or epilepsy serve a variety of purposes . First,  
they are used for identifying novel AEDs. Second, animal models are used to evaluate 
the possible specific efficacies of the compound against different types of seizures or 
epilepsy  if the antiepileptic activity of a novel compound was detected,. Third, specific 
models of AED-resistant seizures are used to investigate whether the novel drug has 
advantages towards clinically established AEDs for therapy of difficult-to-treat types of 
seizures or epilepsies. Fourth, animal models are used to characterize the preclinical 
efficacy of novel compounds during chronic administration. Such chronic studies can 
serve different objectives, for instance evaluation of whether drug efficacy changes 
during prolonged treatment, e.g. because of development of tolerance. Fifth, in view of 
the possibility that chronic brain dysfunctions, such as epilepsy, might lead to altered 
sensitivity to drug adverse effects, models with epileptic animals are useful to study 
whether epileptogenesis alters the adverse effect potential of a given drug. Sixth, animal 
models can be used to estimate effective plasma concentrations of new AEDs for first 
clinical trials. And finally, seventh, animal models are crucial in discovering therapies 
that may prevent or modify the development of epilepsy after brain insults 
 Not all animal models of seizures and/or epilepsy can be used for all of the above 
described purposes. Furthermore, the intention of the experiment is essential for selection 
of a suitable animal model. For instance, simple seizure models such as the maximal 
electroshock seizure (MES) test, allowing to test high numbers of compounds for 
anticonvulsant activity in relatively short time, will be preferred above more complex 
models in screening approaches of anticonvulsant drug development. 
 For AED discovery, which necessitates screening of large numbers of 
compounds, animal models should be easy-to-perform, time- and cost-efficient, and 
predictive of clinical activity. This explains that two simple seizure models in mice and 
rats, the MES and  pentylenetetrazole (PTZ) tests, which have been developed >60 years 
ago, are still the most widely used animal seizure models employed in the search for new 
AEDs.
[7]
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Experimental models 
           These models for testing antiepileptic drugs have also shed light on the 
etiopathogenesis of epilepsy. 
1. Maximal electroshock seizures: Brief  high intensity shock is applied to the head  
of a rodent produces tonic flexion- tonic extension-clonic convulsions. The tonic phase 
(especially extensor) is selectively abolished by drugs effective in generalized tonic 
clonic seizure. Activity in this model represents action on spread of seizure discharge. 
2. Pentylenetetrazol clonic seizures(PTZ) : Injection of  PTZ in rats or mice 
produces clonic convulsions which are prevented by drugs effective in absence seizures. 
Activity in this model represents action on seizure focus itself. 
3. Chronic focal seizures: Produced by application of alumina cream on the motor 
cortex of monkey. 
4. Kindled seizures: Brief bursts of weak electrical impulses are applied to the brain 
(especially amygdala) intermittently over days. After- discharges increase progressively 
and tonic-clonic seizures are produced after 10-15 shocks; with time spontaneous 
seizures have a self perpetuating and reinforcing effect: more neuronal circuits are 
facilitated and recruited in the seizure process. Kindling is probably involved in the 
genesis of clinical epilepsy.
[5]
 
 
1.5 PURPOSE OF THE STUDY 
The current therapy of epilepsy with modern antiepileptic drugs (AEDs) is associated 
with side effects, dose-related and chronic toxicity, as well as teratogenic effects, and 
approximately 30% of the patients continue to have seizures with current antiepileptic 
drugs therapy. The discovery of novel antiepileptic drugs relies upon the preclinical 
employment of animal models to establish efficacy and safety prior to the introduction of 
the AEDs in human volunteers. Natural products from folk remedies have contributed 
significantly in the discovery of modern drugs and can be an alternative source for the 
discovery of AEDs with novel structures and better safety and efficacy profiles. For the 
detection of antiepileptic activity, several plants are used for the treatment of epilepsy in 
different systems of traditional medicine and these plants have shown activity when 
tested in modern bioassays and many such plants are yet to be scientifically investigated. 
Medicinal plants used for the therapy of epilepsy in traditional medicine have been  
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shown to possess promising anticonvulsant activities in animal models of anticonvulsant 
screening.
[8]
Various  studies shows that the active principle alkaloids having a crucial 
role in treatment of epilepsy. Aconitum heterophyllum is rich in diterpene alkaloids
(11)
. 
The purpose of the study is to evaluate the antiepileptic activity of chloform extract of 
Aconitum heterophyllum. 
1.6 HYPOTHESIS 
I hypothesize that the presence of active constituents like diterpene alkaloids in this plant 
Aconitum heterophyllumafter isolation and extraction  may produce anti convulsant 
activity. To test whether the plant producing the anti convulsant activity, MES and PTZ 
induced convulsion models are selected. The result of these studies will have a 
translational value to anti convulsant activity. 
 
1.7 SPECIFIC AIMS 
1. To determine anticonvulsant activity of CEAH by MES and PTZ induced 
convulsion models 
2. To determine in vivo antioxidant activity of CEAH 
3. To determine the effect of CEAH on neurotransmitters level in MES and PTZ 
induced convulsion models. 
 
1.8 PLAN OF WORK 
1. Review of Literatures 
2. Selection, Collection And Authentication of Plant Material 
3. Extraction of plant materials with chloroform 
4. Acute toxicity study 
5. Pharmacological study 
A. Screening of anti epileptic activity using various models 
 Maximal electroshock induced convulsion 
 Pentylenetetrazole induced convulsion 
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            B. Estimation of neurotransmitter 
               a. GABA 
              b. Serotonin  
              c. Nor adrenaline 
              e. Dopamine 
7.Invivo antioxidants 
  Reduced Glutathione ( GSH)  
  Lipid peroxidation (LPO) 
8. Total protein content 
9. Histopathological study 
10. Statistical analysis 
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2.REVIEW OF LITERATURE 
 
2.1. EPILEPSY 
Epilepsy is a chronic CNS disorder characterized by brief episodesof seizures and 
excessive EEG discharge. It is usually associated with loss of consciousness, violent 
spasmodic contractions of skeletal muscles (convulsions) and autonomic hyperactivity.
[9]
 
Epilepsy is one of the most common neurological disorders. Worldwide, the 
prevalence is estimated to be 0.5- 1%, and there is a life time incidence of 1- 3%. It has 
important medical, social and psychological consequences .Epilepsy is a heterogeneous 
symptom complex, a chronic disorder characterized by recurrent seizures. Seizures 
resulting from abnormal discharge of cerebral neurons and are finite episodes of brain 
dysfunction . It is estimated that in India (with population more than 1 billion), there will 
be 6- 10 million people with epilepsy, accounting for nearly 1/5 of global burden. The 
current treatment of epilepsy with modern antiepileptic agents is associated with side 
effects, dose-related and chronic toxicity, as well as teratogenic effects, and 
approximately 30% of the patients continue to have seizures with current antiepileptic 
drugs therapy . Therefore, there is a great need for the development of cheap, effective 
and safe anticonvulsant agents from plants and other sources.
[10] 
 
2.2 NATURE OF EPILEPSY 
The term epilepsy  is used to define a group of neurological disorders all of which 
exhibit periodic seizures. Not all seizures involve convulsions. Seizures are associated 
with episodic high-frequency discharge of impulses by a group of neurons (sometimes 
referred to as focus) in the brain. What starts as a local abnormal discharge may then 
spread to other areas of the brain. The site of the primary discharge and the extent of its 
spread determine the symptoms that are produced, which range from a brief lapse of 
attention to a full convulsive fit lasting for several minutes, as well as odd sensations or 
behaviours. 
 The particular symptoms produced depend on the function of the region of the 
brain that is affected. Thus, involvement of the motor cortex causes convulsions, 
involvement of the hypothalamus causes peripheral autonomic discharge, and 
involvement of the reticular formation in the upper brain stem lead to loss of 
consciousness.
[11] 
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2.3TYPES 
A. Generalised seizures 
1. Generalized tonic-clonic seizures(major epilepsy, grand mal): commonest, 
lasts 1-2 min. Prolonged sleep and depression of all CNS functions after the usual 
sequence that is aura-cry-unconsciousness-tonic spasm of all body muscles-clonic 
jerking followed by  
2. Absence seizures (minor epilepsy, petit mal): prevalent in children, lasts about 
½ min. Sudden loss of consciousness, no muscular component or little bilateral jerking, 
patient apparently freezes and stares in one direction,.  
3. Atonic seizures (Akinetic epilepsy): unconsciousness with relaxation of all 
muscles due to excessive inhibitory discharges. Patient may fall. 
4. Myoclonic seizures: shock-like momentary contractions of muscles of a limb or 
the whole body. 
5. Infantile spasms (Hypsarrhythmia):  these type of epilepsy seen in infants and 
probably not a form of epilepsy.Intermittent muscle spasm and progressive mental 
deterioration. 
B. Partial seizures 
1. Simple partial seizures (cortical focal epilepsy): lasts ½-1 min. Often 
secondary. Depending on the area of cortex involved, convulsions are confined to a 
group of muscles or localized sensory disturbance, without loss of consciousness. 
2. Complex partial seizures (temporal lobe epilepsy): attacks of bizarre and 
confused behaviour and purposeless movements, emotional changes lasting 1-2 min 
along with impairment of consciousness. An aura often precedes. The seizure focus is 
located in the temporal lobe. 
3. Simple partial or complex partial seizures secondarily generalized: The 
partial seizure occurs first and evolves into generalized tonic clonic seizures with loss of 
consciousness.
[5]
 
 
2.4 CAUSES 
             All forms of epilepsy have their origin in the brain. The different types of 
epilepsies are not based on a single underlying mechanism, but are multifactorial in 
origin. Epilepsy results when many neurons in union, under a high excited stage, deliver  
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massive discharges abolishing a finely organized pattern of the integrative activity of the 
brain.  
John Jackson proposed that these seizures are caused by occasional, sudden, 
excessive, rapid and local discharges of grey matter and once initiate by the abnormal 
focus, the seizures attack the neighboring normal brain resulting into generalized 
convulsions. This abnormal focus may originate as a result of local biochemical changes, 
ischemia or the loss of vulnerable cell inhibitory systems. However, certain physiological 
changes may trigger the focus and thus facilitate the spread of abnormal electrical 
activity to normal tissue. Such factors include 
 Changes in blood glucose concentration 
 Plasma pH 
 Total osmotic pressure and electrolytes composition of extra cellular fluids 
 Fatigue 
 Emotional stress 
 Nutritional deficiency.[4] 
 Genetic Factors 
           Several types of epilepsy have now been linked to defective genes for ion 
channels, the "gates" that control the flow of ions in and out of cells and regulate neuron 
signaling. Another gene, which is missing in people with progressive myoclonus 
epilepsy, codes for a protein called cystatin B. This protein regulates enzymes that break 
down other proteins. Another gene, which is altered in a severe form of epilepsy called 
LaFora's disease, has been linked to a gene that helps to break down carbohydrates. 
 Other Disorders 
In some cases, epilepsy may develops as a result of brain damage from other 
diseases. For example, brain tumors, alcoholism, and Alzheimer's disease frequently lead 
to epilepsy because they alter the normal workings of the brain. Strokes, heart attacks, 
and other conditions that diminishes the supply of oxygen towards brain, also can cause 
epilepsy in some cases. About 32 percent of all cases of newly developed epilepsy in 
elderly people appears to be due to cerebrovascular disease, which reduces the supply of 
oxygen to brain cells. Meningitis, AIDS, viral encephalitis, and other infectious diseases 
and also ahydrocephalus -- a condition in which excess fluid builds up in the brain can  
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lead to epilepsy. Epilepsy also can result from intolerance to wheat gluten (also known as 
celiac disease), or from a parasitic infection of the brain known as neurocysticercosis.  
Epilepsy is having connection  with a variety of  metabolic diseases  such as 
cerebral palsy, pyruvate dependency, tuberous sclerosis, Landau-Kleffner syndrome, and 
autism. Epilepsy is just one of a set of symptoms commonly found in people with these 
disorders. 
 Head Injury 
 Prenatal Injury and Developmental Problems 
             The developing brain is susceptible to many kinds of injury. Some conditions 
like Maternal infections, poor nutrition, and oxygen deficiencies that may affect the brain 
of a developing baby. These conditions may lead to cerebral palsy, which often is 
associated with epilepsy, or they may cause epilepsy that is unrelated to any other 
disorders.  
 Poisoning 
Exposure to lead, carbon monoxide, and many other poisons may cause seizures. 
They also can result from exposure to street drugs and from overdoses of antidepressants 
and other medications. 
            Seizures are often triggered by factors such as lack of sleep, alcohol 
consumption, stress, or hormonal changes associated with the menstrual cycle. For some 
people, a seizure can also be triggered by light flashing at a certain speed or the flicker of 
a computer monitor and  this problemthis type of epilepsy is known as photosensitive 
epilepsy. Smoking cigarettes also can trigger seizures. The nicotine in cigarettes acts on 
receptors for the excitatory neurotransmitter acetylcholine in the brain, which increases 
neuronal firing. Seizures are not triggered by sexual activity except in very rare 
instances.
[2] 
Aetiologically, the epilepsies are classified into four groups: idiopathic, 
symptomatic, cryptogenic and progressive . The idiopathic epilepsies are thought to be 
genetically determined and are usually associated with particular clinical characteristic 
and specific electroencephalography (EEG) findings . Structural abnormality of the brain 
can result in symptomatic epilepsies and are acquired condition . Epilepsy is classified as 
cryptogenic when no clear abnormality or putative risk factor is identified for what is  
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presumed to be a symptomatic or acquired epileptic condition . The term progressive 
epilepsy is used when epilepsy is associated with an evolving neurological condition.
[12]
 
 
2.5 SYMPTOMS 
Repeated seizure is the major cause of epilepsy. The individual should see a 
doctor If one or more of the following symptoms are present, especially if the symptoms 
recur: 
 a convulsion with no temperature (no fever) 
  Confused memory or short spells of blackout  
 intermittent fainting spells, during which loss of bowel or bladder control,  
followed by extreme tiredness 
 for a short period, the person is unresponsive to instructions or questions 
 the person becomes stiff, suddenly, for no apparent reason 
 the person suddenly falls  
  the person shows sudden bouts of blinking without apparent stimuli 
 sudden bouts of chewing, without any apparent reason 
 for a short time the person seems dazed and unable to communicate 
 repetitive movements that seem inappropriate 
 the person becomes fearful for no apparent reason; they may even panic or 
become angry 
 peculiar changes in senses, such as smell, touch, and sound 
 the arms, legs, or body jerk, in babies these will appear as a cluster of rapid 
jerking movements 
The following conditions need to be eliminated as they may appear as similar 
symptoms and are sometimes misdiagnosed as epilepsy: 
 high fever with epilepsy-like symptoms 
 fainting 
 narcolepsy - recurring episodes of sleep during the day 
 cataplexy - periods of extreme weakness 
 sleep disorders 
 nightmares 
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 panic attacks 
 fugue states - rare psychiatric disorder 
 psychogenic seizures[13] 
 
2.6SYNDROMES 
 Cases of epilepsy may be arranged into epilepsy syndromes on the basis of 
specific features that are present. These features include, the seizure types, EEG findings, 
the age that seizure begins. Identifying an epilepsy syndrome is useful as it helps 
determine the underlying causes as well as what anti-seizure medication should be tried. 
Since the onset of seizures is commonly early, the ability to categorize a case of 
epilepsy into a specific syndrome occurs more often with children. Less serious 
examples are benign rolandic epilepsy (2.8 per 100,000), childhood absence epilepsy 
(0.8 per 100,000) and juvenile myoclonic epilepsy (0.7 per 100,000). Severe syndromes 
with diffuse brain dysfunction caused, at least partly, by some aspect of epilepsy, are also 
commonly known as epileptic encephalopathies. These are associated with frequent 
seizures that are resistant to treatment and severe cognitive dysfunction, for instance 
Lennox–Gastaut syndrome and West syndrome. Genetics is believed to play an 
important role in epilepsies by a number of mechanisms. Simple and complex modes of 
inheritance have been identified for some of them. However, extensive screening have 
failed to identify many single gene variants of large effect.  
Syndromes in which causes are not clearly identified are difficult to match with 
categories of the current classification of epilepsy. Categorization for these cases was 
made somewhat arbitrarily. In case of 2011 classification (idiopathic category)  includes 
syndromes in which the general clinical features and/or age specificity strongly point 
towards a genetic cause. Some childhood epilepsy syndromes are included in the 
unknown cause category in which the cause is presumed genetic, for instance benign 
rolandic epilepsy. Others are included in symptomatic in some cases despite a presumed 
genetic cause, for example Lennox-Gastaut syndrome. Clinical syndromes in which 
epilepsy is not the main feature (e.g. Angelman syndrome) were categorized 
symptomatic but it was argued to include these within the category idiopathic. 
Classification of epilepsies and particularly of epilepsy syndromes will change with 
advances in research.
[14]
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2.7  PATHOPHYSIOLOGY 
 Action potential is the the basic mechanism of neuronal excitability . Action 
potential is a hyperexcitable state can result from increased excitatory synaptic 
neurotransmission, decreased inhibitory neurotransmission, an alteration in voltage-gated 
ion channels, or an alteration of intra- or extra-cellular ion concentrations in favor of 
membrane depolarization. Membrane potential can varies with activation of ligand- 
gated channels, whose conductance is affected by binding to neurotransmitters; or with 
activation of voltage-gated channels, whose conductance is affected by changes in 
transmembrane potential; or with changes in intracellular ion compartmentalization. 
             The major neurotransmitters in the brain are glutamate, gamma-amino-butyric 
acid (GABA), acetylcholine (ACh), norepinephrine, dopamine, serotonin, and histamine. 
The major excitatory neurotransmitter is the amino acid glutamate. All ionotropic 
glutamate receptors are permeable to Na+ and K+, and it is the influx of Na+ and 
outflow of K+ through these channels that contribute to membrane depolarization and 
generation of the action potential. The NMDA receptor also has a Calcium channel and 
in resting state, calcium channel is blocked by Magnesium ions, but under conditions of 
local membrane depolarization, Mg++ is displaced and the channel becomes permeable 
to Ca++. Influx of Ca++ tends to further depolarize the cell, and is thought also to 
contribute to Ca++ mediated neuronal injury under conditions of excessive neuronal 
activation (such as status epilepticus and ischemia), potentially leading to cell death, a 
process termed excitotoxicity.   
            The major inhibitory neurotransmitter, GABA, interacts with 2 major subtypes of 
receptor: 
GABAA and GABAB receptors. GABAA receptors are found postsynaptically, 
while GABAB receptors are found presynaptically, and can thereby modulate synaptic 
release. GABAA receptors are permeable to Cl- ions in adult brain and action potential is 
inhibited by upon activation Cl- influx hyperpolarizes the membrane. Therefore, 
substances which are GABAA receptor agonists, such as barbiturates and 
benzodiazepines, are well known to suppress seizure activity. Rather than Cl- channels, 
GABAB receptors are associated with second messenger systems, and due to their 
presynaptic location, attenuation of transmitter release occurs. The second messenger 
systems often result in opening of K+ channels, leading to a hyperpolarizing current.  
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Certain GABAB agonists, such as baclofen, have been reported to exacerbate 
hyperexcitability and seizures.
[15]
 
 
Figure-1: Pathophysiology of epilepsy 
 
 
2.8 DIAGNOSIS 
Abnormal electrical activity during and following a seizure can be detected by 
electroencephalography (EEG) recording from electrodes distributed over the surface of 
the scalp. Various types of seizure can be recognized on the basis of the nature and 
distribution of the abnormal discharge. Modern brain imaging techniques, such as 
magnetic resonance imaging and positron emission tomography, are now routinely used 
in the diagnosis of epilepsy to identify structural abnormalities(eg. Lesions, tumors) that 
cause certain epilepsies.
[11] 
 
2.9TREATMENT 
  Once epilepsy is diagnosed, it is important to begin treatment as soon as possible. 
Once seizures and their consequences become established, research suggests that current 
available medication and other treatments may be less successful in treating epilepsy. 
 Medications 
By far the most common approach to treating epilepsy is to prescribe 
antiepileptic drugs. Doctors diagonosing a patient with newly developed epilepsy often  
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prescribe antiepileptic agents like carbamazepine, valproate, lamotrigine, oxcarbazepine, 
or phenytoin first, unless the developed epilepsy is a type that is known to require a 
different kind of treatment. For absence seizures, ethosuximide is often the primary 
treatment. Other commonly prescribed drugs include clonazepam, phenobarbital, and 
primidone. Some relatively new epilepsy drugs include tiagabine, gabapentin, 
topiramate, levetiracetam, and felbamate.
[2]
 
 
 Classification 
1. Barbiturate:  Phenobarbitone 
2. Deoxybarbiturate: Primidone 
3. Hydantoin: Phenytoin, Fosphenytoin 
4. Iminostilbene: Carbamazepine, Oxcarbazepine 
5. Succinimide: Ethosuximide 
6. Aliphatic carboxylic acid: Valproic acid, Divalproex 
7. Benzodiazepines: Clonazepam, Diazepam, Lorazepam, Clobazam 
8. Phenyltriazine: Lamotrigine 
9. Cyclic GABA analogues: Gabapentin, Pregabalin 
10. Newer drugs: Topiramate, Zonisamide, Tiagabine[5] 
 
2.10 MECHANISM OF ACTION 
  The currently available anticonvulsant agents are thought to act by three main 
mechanisms: 
1. Reducing electrical excitability of cell membranes, mainly through use-
dependent block of sodium channels 
2. Enhancing GABA-mediated synaptic inhibition; this may be achieved by an 
enhanced postsynaptic actionof GABA, by inhibiting GABA transaminase or 
by inhibiting GABA uptake into neurons and glial cells 
3. Inhibiting T-type calcium channels (important in controlling absence 
seizures). 
 Newer drugs act by other mechanisms, largely yet to be elucidated. 
 Drugs that block ionotropic glutamate receptors are effective in animal models 
but are unsuitable for clinical use.
[11]
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Figure-2: Mechanism of action of Antiepileptic drugs 
 
 
 
 Surgery to treat underlying conditions 
When seizures are caused by a brain tumor, hydrocephalus, or other conditions 
that can be treated with surgery, doctors may operate to treat these underlying 
conditions. In many cases, once the underlying condition is successfully treated, a 
person's seizures will disappear as well. 
 
 Surgery to remove a seizure focu 
  Removal of a seizure focus, or small area of the brain where seizures originate is   
the most common type of surgery for epilepsy. This type of surgery, which doctors                        
may refer to as a lobectomy or lesionectomy, is appropriate only for focal seizures 
that originate in just one area of the brain.  
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Indications of surgery 
1. Medically intractable seizures 
2. Seizures significantly affect the quality of life 
3. Localized seizure focus 
4. Presence of signs predictable of seizure persistence 
 
Contraindications of surgery 
1. Benign, self limited epilepsy syndrome 
2. Neurodegenerative and metabolic disorders 
3. Non compliance with drugs 
4. Severe family disfunctions 
5. Associated psychosis 
 
 Multiple subpial transection 
            When seizures originate in part of the brain that cannot be removed, surgeons 
may perform a procedure called a multiple subpial transection 
 
 Corpus callosotomy 
           In children with severe seizures that start in one half of the brain and spread to the 
other side, Corpus callosotomy, or severing the network of neural connections between 
the right and left halves, or hemispheres, of the brain, is done. 
 
 Hemispherectomy and hemispherotomy 
           These procedures remove half of the brain's cortex, or outer layer. These are used 
mainly  in children who are suffering from seizures that do not  show response to 
medication because of damage that involves only half the brain, as occurs with 
conditions such as Rasmussen's encephalitis, Sturge-Weber syndrome, and 
hemimegencephaly 
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 Devices 
          The vagus nerve stimulator was approved by the U.S. Food and Drug 
Administration (FDA) in 1997 for use in people with seizures that are not well-controlled 
by medication. The vagus nerve stimulator is a battery-powered device that is surgically  
implanted under the skin of the chest, much like a pacemaker, and is attached to the 
vagus nerve in the lower neck. This device delivers short bursts of electrical energy to  
the brain via the vagus nerve. Researchers are studying whether transcranial magnetic 
stimulation (TMS), a procedure which uses a strong magnet held outside the head to 
influence brain activity, may reduce seizures. They also hope to develop implantable 
devices that can deliver drugs to specific parts of the brain.
[2]
 
 
 Diet 
Ketogenic diet is one of the oldest methods of treating childhood epilepsy. In children 
with refractory seizures who have failed drug therapy and are not candidate for epilepsy 
surgery, this therapy is as or more effective than the addition of new anti-epileptic drug. 
For example, it remains a reasonable alternative for children with Lennox-Gastaut 
syndrome refractory to standard drug therapy.  
The ketogenicdiet consist of a higher proportion of fats and small amounts of 
carbohydrates and protein. The basis of the therapeutic effectiveness of the ketogenic 
diet is because of the ketosis that develops when the brain is relatively deprived of 
glucose as an energy source and must shift to utilization of ketone bodies as the primary 
fuel.  
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Figure-3: Therapeutic strategies for managing newly diagnosed epilepsy
[16] 
 
Newly diagnosed epilepsy  
 Consider starting therapy after the second seizure  
 
 
First choice drug 
 Choose drug appropriate for the patient’s type of seizure. 
1. Consider toxicities of the agent  
2. Consider characteristics of the patient 
 Gradually titrate the dosage to that which is maximally tolerated and/ or produces optimal 
seizure control. 
 
 
 
 
Seizure free 
 
 
Second choice drug 
 The second drug is titrated to a therapeutic level that controls seizures before tapering and 
discontinuing the original antiseizure agent 
 If the first drug is associated with associated with significant adverse effects, it should be 
tapered while the second drug is added. 
 
 
 
 
Rational combination of two drugs 
 
 
Seizures persist 
Seizure persist Seizure free 
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2.11ANTIEPILEPSY ACTIVITY 
 Avanthi E et al., (2016) evaluated the antiepileptic activity of clove oil by MES 
model in mice. A total of  thirty mice were taken, they were given an 
electroconvulsive shock. Thirty mice were divided into five groups of six animals 
each, the control group received distilled water 5ml/kg i.p, standard received Inj. 
Sodium valproate 200 mg/kg i.p. another group received Sesame oil – 10ml/kg 
i.p(control), test groups received Clove oil- 0.075 ml/kg i.p., Clove oil-0.1ml/kg 
i.p respectively. All the injections were given 30 minutes before the test. The 
results showed Clove oil produced significant antiepileptic effect at all the 
doses.
[17]
 
 
 K Sandeep Kumar et al., (2015) evaluated the antiepileptic activity of ethanolic 
extract of Biophytum sensitivum in animal models. The anticonvulsant activity 
was assessed using MES and PTZ using albino mice. The extract reduced the 
duration of tonic hind limb extension and delayed  the onset of tonic clonic 
convulsion. The result showed that the ethanolic extract of the plant beneficial in 
both tonic clonic and absence seizures.
[10]
 
 
 Nirmala D (2015) performed a study which involves in detecting anticonvulsant 
activity from Annacyclus pyrethrum roots by using maximal electroshock seizure 
(MES) in a dose-dependent way. MES-induced tonic seizures can be prevented 
either by drugs that inhibit voltage dependent Na+ channels, such as phenytoin, 
valproate and lamotrigine or by drugs that block glutamatergic excitation 
mediated by the NMDA receptor such as felbamate. The study showed that 
ethanolic extract from roots of A. pyrethrum can inhibit voltage dependent Na+ 
channels as phenytoin in MES induced tonic seizures.
[18]
 
 
 Gummalla Pitchaiahet al., (2015) evaluated the anticonvulsant activity of 
methanolic extract of Allium cepa (Onion) bulbs in Swiss albino mice. The 
anticonvulsant effect was assessed using maximal electroshock (MES) and  
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Isoniazid(INH) induced seizure models. Methanolic extract (200 and 400 mg/kg) 
showed significant reduction in the duration of hind limb extensor phase in 
electroshock convulsions; protected the mice against the Isoniazid induced 
convulsions. The results showed significant improvement in brain GABA levels 
after Allium cepa treatment.
[19]
 
 
 Santilna K S et al., (2014) studied the anticonvulsant activity study of Artemisia 
nilagirica. The leaves part of the plant was dried, powdered and subjected to 
maceration using diethyl ether, chloroform and ethanol. The results showed that 
the alkaloids, flavonoids and terpenoids were identified to be present in all three 
solvents extracts. The result obtained suggests that the ethanolic and chloroform 
extracts of Artemisia nilagirica may be beneficial in the treatment of epilepsy.
[20]
 
 
 Ravindra C Sutar et al., (2014) evaluated the anticonvulsant activity of leaf 
extract of Holoptelea integrifolia. The petroleum ether and methanolic extract of 
the leaves was evaluated using Pentylenetetrazole (PTZ) induced convulsions in 
mice and maximal electro shock (MES) induced Convulsions and lithium-
pilocarpine induced status epilepticus in rats. The petroleum ether extract and 
methanolic extract delayed onset of PTZ- induced convulsions and also 
prolonged the onset of tonic convulsions in mice. Both the extracts failed to 
protect the rats from MES induced convulsions. The extracts also protected rats 
against seizures induced by lithium-pilocarpine. The results indicate that 
petroleum ether and methanol extracts contained such phytochemial compounds 
which are active in case of Pentylenetetrazole (PTZ) and lithium pilocarpine 
induced status epilepticus, which support the ethnomedicinal application of the 
plant as an anticonvulsant agent.
[21]
 
 
 DilnawazPathanet al., (2014) evaluated the anticonvulsant effect of ethanolic 
extract of roots of  Picrorhiza kurroa on electrically and chemically induced 
seizures. The extract was studied for its anticonvulsant effect on maximal 
electroshock-induced seizures and pentylenetetrazole, picrotoxin induced seizures  
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in mice. It has been observed in the present study that extract(100 mg/kg) showed 
significant increase in latency to clonic convulsions and reduced mortality. The 
results shows that Picrorhizakurroa possess anticonvulsant activity against 
Pentylenetetrazole , Maximal electroshock  and Picrotoxin induced convulsions 
in mice.
[22]
 
 
 Ganapathi G. Varmaet al., (2014) performed the evaluation of antiepileptic 
activity of methanolic leaves extract of Tragia involucrata  in mice. In vivo 
screening models like maximal electroshock-induced convulsion (MES), 
pentylenetetrazole (PTZ) and picrotoxin (PTX) induced models are used to 
evaluate the antiepileptic effects of the extracts. In the MES induced convulsion, 
methanolic extract (800 mg/kg), showed high significant inhibition on tonic hind 
limb extension and decrease in duration of stupor period . In PTZ and PTX 
induced model extract(400 mg/kg and 800 mg/kg) showed delay on the onset of 
convulsions, decreased duration of convulsion and reduced mortality 
significantly. The results showed that Tragiainvolucrata possesses dose 
dependent antiepileptic activity.
[23]
 
 
 MehrdadModaresi et al., (2014) studied the antiepileptic activity of 
hydroalcoholic extract of Ocimum basilicum in mice. The experimental groups 
comprised control, sham, and four treatment groups receiving the extract at 100, 
250, 300, and 350 mg/kg doses 65 minutes before PTZ injection. The obtained 
results of using different doses of the extract indicated that the mice receiving the 
extract at 100 and 250 mg/kg doses exhibited the highest and lowest frequency of 
myoclonic twitches, respectively.
[24]
 
 
 Chinchawade A B et al., (2013) observed the anticonvulsant activity of 
chloroform extract of bark & root of Erythrina variegate. The pentyleneterazole 
(PTZ) and the maximal electroshock seizure (MES) models were used for 
assessing the anticonvulsant effects of the chloroform extract in mice and rats. 
The extract produced significant protection against PTZ-induced and MES-
induced convulsions in rat. The results obtained from this study indicate that the  
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chloroform root and bark extract of Erythrinavariegata may be beneficial in both 
absence and tonic clonic seizures.
[25]
 
 
 Abubakar K et al., (2013) evaluated the anticonvulsant effect of methanolic 
extract of  Evolvulus alsinoides in mice using pentyleneterazole (PTZ) and the 
maximal electroshock seizure (MES) model. The extract significantly increased 
the latency of  PTZ  induced seizure. In the MES test a dose dependent decrease 
in the duration of seizure was also observed. These findings suggest that the 
methanol extract of the plant contains bioactive principles that may be beneficial 
in the treatment of epilepsy.
[26]
 
 
 Ashish P Anovadiya et al., (2013) performed the antiepileptic and memory 
retention activity of Curcumin perse and in combination with antiepileptic drugs. 
In this study, antiepileptic activity of curcumin and its combination with 
phenytoin and sodium valproate were studied in chronic model (14 days) of 
Maximal Electroshock Seizure (MES) and Pentylenetetrazole (PTZ) induced 
seizure respectively. Curcumin (100 mg/kg) reduced clonic phase and 
significantly inhibited PTZ induced seizure. Addition of curcumin to sub 
therapeutic dose of sodium valproate showed synergistic effect..Curcumin found 
to be effective in absence seizure alone and as add on with sodium valproate.
[27]
 
 
 Prabhat Singh et al., (2012) studied antiepileptic activity of aqueous extract of 
fruits of Tricosanthes dioica. The antiepileptic efficacy of aqueous extract was 
evaluated by hand limb extension induced by MES and PTZ induced seizures in 
mice models. The aqueous extract was showed significant antiepileptic activity in 
both models and it was found to be due to activity against generalized tonic- 
clonic and cortical focal seizures.
[28]
 
 
 Vikas Saroch et al., (2012) evaluated the anticonvulsant Activity of Apasmarari 
rasa. Apasmarari rasa was subjected to assess the LD 50 and Anti convulsant 
activity on Male Albino rats was by means of MES (Maximal Electro convulsing 
Shock) Method. A supramaximal strength was 150mA in rats for 0.2 seconds and  
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stimulus was applied via ear clip electrodes. The animal dose of Phenytoin  
(7.2mg/kg), Smritisagar rasa (18mg/kg) and Apasmarari rasa (5.4mg/ kg) was 
given orally to different groups. The animals were observed for a period of 180 
minutes after being subjected to electro convulsions. Both standard drugs also 
shown good results when it comes to HLE (hind limb extension), butother factors 
such as time duration of flexion, tonus, clonus, recovery time amongst others in 
test drug group (Apasmarari rasa) showed significantly better results.
[29]
 
 
 Vipin K Garget al., (2011) evaluated the anticonvulsant activity of ethanolic 
extract of Cynodon dactylon. The  anticonvulsant activity was studied using 
maximal electroshock (MES) and Pentylenetetrazol (PTZ) induced convulsions 
in mice. The extract suppressed hind limb tonic extensions (HLTE) induced by 
MES and also exhibited protector effect in PTZ-induced seizures. The results 
showed that the ethanolic extract of Cynodon dactylon has anticonvulsant effect 
in the both models suggesting their possible depressant action in the central 
nervous system.
[30]
 
 
 Shyamjith Manikkoth et al., (2011) performed Phyllanthus amarus on maximal 
electroshock-induced seizures (MES) and pentylenetetrazole (PTZ) induced 
seizures. The aqueous and ethanolic extracts of the leaves and stems of P. amarus 
significantly abolished the hind limb extension induced by MES. The same dose 
also significantly protected the animals from PTZ induced tonic convulsions.
[31]
 
 
 Harish Babu B et al., (2010) performed  anticonvulsant activity of the 
methanolic extract of Martynia annua  on Maximal Electroshock(MES) and 
Pentylenetetrazole (PTZ) induced seizures models in albino wistar rats. These 
studies showed, the mean duration of extensor phase of test group reduced to 
significant level as compared to control group. In Pentylenetetrazol induced 
seizure test, onset of myoclonic spasm and clonic convulsion was delayed in the 
test group. The study concluded  Martynia annua possesses an anticonvulsant 
effect which results from the potentiation of the activity of GABA.
[32]
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 N. S. Vyawahareet al., (2009) evaluated the anticonvulsant activity of roots of 
Argyreia speciosa in mice. The mice were pretreated with different doses of 
Argyreia speciosa  extract for 10 days and then, they were subjected to either 
pentylenetetrazole or maximal electroshock seizures treatment. The 
hydroalcoholic extract of Argyreia speciosa at the dose of 200 and 400 mg/kg 
significantly delayed the latency to the onset of first clonus and significantly 
reduced the duration of hind limb extension. This study shows that the 
hydroalcoholic extract possesses anticonvulsant activity against 
pentylenetetrazole and maximal electroshock seizures.
[33]
 
 
 KarunakarHegde et al., (2009) studied the anticonvulsant activity of Carissa 
carandas root extract in experimental mice. The ethanolicextract  was studied for 
its anticonvulsant effect on maximal electroshock-induced seizures and 
pentylenetetrazole-, picrotoxin-, bicuculline- and N-methyl-dl-aspartic acid-
induced seizures in mice. The data suggest that the ethanolic root extract reduced 
the duration of seizures produced by maximal electroshock as well as delayed the 
latency of seizures produced by pentylenetetrazole and picrotoxin.
[34]
 
 
2.12 Aconitumheterophyllum 
 S. G. Budhadev et al., (2017) studied a complete review on Ativisha- Aconitum 
heterophyllum. The phytochemical constituents of Aconitum heterophyllum were 
isolated and characterized with the help of chromatographic separation technique 
and their structures were explained by using nuclear magnetic resonance 
techniques. The plant possess ant-inflammatory activity which was evaluated by 
using cotton pellet granuloma method.
[35]
 
 DebashishParamanick et al., (2017) studied the phytochemistry and 
pharmacognosy as well as the medicinal properties of Aconitum heterophyllum. 
Aconitum heterophyllum has been used in some formulations in the traditional 
healing system of India (Ayurveda). It was reported to have use in treating 
patients with urinary infection, diarrhea and inflammation. The plant has been 
also used as an expectorent and for the promotion of hepatoprotective activity.  
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The chemical studies of plant have revealed that it contain alkaloids, saponins, 
glycosides, flavonoids etc.
[36]
 
 Neeraj Sharma et al., (2017) performed an attempt to assemble all the 
information on Aconitum heterophyllum such as botanical, photochemical, 
pharmacological and toxicological. It possess many pharmacological property 
such as antioxidant, anti-inflammatory, anti-periodic, expectorant etc. but most 
species of Aconitum are highly toxic in nature. Aconitum heterophyllum is the 
intoxicating source of phytochemical constituents that are responsible for its 
pharmacological activities.
[37]
 
 Rajakrishnan R et al., (2016) performed the standardization of the root tubers of 
Aconitum heterophyllum as per pharmacopoeial testing protocol which include 
powder microscopy, physic-chemical screening, HPTLC fingerprinting and GC-
MS analysis. Preliminary phytochemical test showed the presence of alkaloids, 
sugars, flavonoids, steroids, quinones and tannins. The GC-MS analysis of the 
diethyl ether fraction showed the presence of 39 compounds of which 21 were 
identified.
[38]
 
 M. Nagarajanet al., (2015) evaluated the pharmacology of Aconitum 
heterophyllum and three other species. The biological properties of Ativisha and 
Musta are similar according to ayurvedic classification of dravyaguna. This is 
supported by modern pharmacological studies, which show, both A. 
heterophyllum and C. rotundus have antidiarrheal, antipyretic, anti-inflammatory, 
antihyperlipidemic and hypoglycemic activities. The dravyaguna method of 
classifying materials (pharmaco-taxonamy), offer a unique way of classifying 
plant materials.
[39]
 
 Sadia Khurshid et al., (2015) studied clinical and therapeutic potential of 
Aconitum heterophyllum. The constituents of Aconitum heterophyllum such as 
alkaloids, flavonoids, diterpenoid and nonditerpenoid compounds were isolated 
and characterized by using chromatographic separation techniques. The study of 
the structure of these compounds were done by the technique of nuclear magnetic 
resonance. The anti-inflammatory activity of ethanolic root extract of Aconitum  
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heterophyllum was determined by cotton pellet induced granuloma in rats. The 
results revealed the activity.
[40]
 
 Satyendra K Prasad et al., (2014) evaluated anti diarrheal activity of ethanol 
extract of Aconitum heterophyllum at 50, 100 and 200 mg/kg using fecal 
excretion and castor oil induced diarrheal models. The results depicted a 
significant reduction in normal fecal output. The study concluded antisecretory 
and antimotility effect of Aconitum heterophyllum, which mediates  through nitric 
oxide pathway.
[41]
 
 Neelma Munir et al., (2014) studied the antifungal and antioxidant activity of 
Aconitum heterophyllum. The invivo antifungal activity of Aconitum 
heterophyllum were determined by measuring diameters of inhibitory zones of 
the extract against Aspergillusniger and Alternaliasolani. The methanolic extract 
of  Aconitum heterophyllum showed significant antifungal activity against both 
the tested organisms. The extract also showed antioxidant activity, measured 
using a radical scavenging method.
[42]
 
 Yoirentimameetei et al., (2014) performed the antibacterial activity of the root 
alkaloid extract of Aconitum heterophyllum. This alkaloid  extract showed 
antibacterial activity against  S. aureus, B. bronchiseptica, B. subtilis, P. putida 
and X. campestris. The present study revealed the antibacterial activity of all 
alkalids from root was due to synergistic effect of different alkaloids.
[43]
 
 S John Adams et al., (2013) performed a study including the establishment of 
pharmacognostic and phytochemical characters of Aconitum heterophyllum and 
to compare with its substitutes. They performed histological, phytochemical tests 
using standard protocols. Based on histochemical analyses, it was revealed the 
presence of alkaloid, terpenoid-alkaloid complex, lipids and calcium majorly.
[44]
 
 Venu GopalaRao Konda et al., (2013) evaluated the hepatoprotective activity of 
ethanolic extract of Aconitum heterophyllum root in Parecetamol induced hepatic 
damage in wistar albino rats. The hepatoprotective activity of ethanolic extract of 
Aconitum heterophyllum root was evaluated by the assessment of biochemical  
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parameters such as SGOT, SGPT, ALP, total bilirubin, serum protein and 
histopathological studies of the liver. Ethanolic extract of the Aconitum 
heterophyllum root significantly reduced the liver damage and  all biochemical 
parameters.
[45]
 
 Arunkoorapilly et al., (2012) evaluated the hypolipidemic effect of methanol 
fraction of Aconitum heterophyllum wall. The administration of Aconitum 
heterophyllum was able to reduce serum TG, LDL-C  levels. Furthermore, 
Aconitum heterophyllum help to improve lipid HDL-C level. The results shows 
that the change in lipid profile by Aconitum heterophyllum is due to the inhibition 
of HMGR and the activation of LCAT enzymes. The extract also able to block 
intestinal fat absorption which helps to reduce cholesterol level. Hence,  
Aconitum heterophyllum methanol fraction exhibits potential hypolipidemic 
activity.
[46]
 
 Satyendra K Prasad et al (2012) performed physicochemical standardization 
and evaluation of in-vitro antioxidant activity of Aconitum heterophyllum. The 
quantitative estimations shows that the root to be highly rich in alkaloids while 
phenols, tannins, flavonoids and saponins were found in less quantity. The in-
vitro antioxidant study showed a moderate to low activity in all models which 
may be due to low phenolic and flavonoid content.
[47]
 
 Santhosh Varma etal., (2010) evaluated the anti- inflammatory activity of 
Aconitum heterophyllum on cotton pellet induced granuloma in rats. The anti-
inflammatory activity of ethanolic root extract of Aconitum heterophyllum (225, 
450 and 900 mg/kg p.o ) has reduced inflammation as evidenced by decreased 
weight of cotton pellet granuloma in rats.
[48]
 
 
 M D Ukaniet al., (1996) studied pharmacology of Aconitum heterophyllum 
(ativisha) of family Ranunculacea, the plant is an ayurvedic herb which is known 
for its medicinal properties. The roots of the plant found use in one form/ the 
other in various ayurvedic preparations. It found to possesss activities like 
antimalarial, anti-inflammatory, antidiabetic, diuretic etc. The constituents of  
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Aconitum heterophyllum include atisine, atidine, heteratisine, heterophylline 
etc.
[49]
 
 
2.13 PLANT PROFILE 
Plant name                  :  Aconitum heterophyllum 
Family                          : Ranunculaceae 
Synonyms                     : Aruna, Ardra, Upavisa, KasayaKrsna, Ghuna 
Vallabha, Pita vallabha,  Prati visa, Bhangura 
Vernacular names       
 English                : Atis root 
 Hindi                   : Atis 
 Kannada              : Ativisa 
 Malayalam          : Ativitayam 
 Sanskrit               : Ativisa 
 Tamil                   : Ativadayam 
 Telungu               : Ativasa 
 
Natural habitat and distribution 
Common in the alpine and sub alpine belts of Himalayan altitudes between 1800 
and 4500 km 
 
Morphology  
Roots: biennial, paired, tuberous; whitish or grey. 
Stem: erect, simple or branched, from 15-20 cm high. glabrous below, finely 
crispo-pubescent in the upper part. 
Leaves: heteromorphous, glabrous: lowest on long petioles (13cm); blade 
orbicular- cordate or ovate-cordate in outline with a usually narrow sinus (1-1.5 
cm deep); usually 5- lobed to the middle, amplexicaul. 
Inflorescence: slender raceme or a lax, leafy panicle, crispo-pubescent; Sepals: 
bluish or violet (rarely whitish); navicular obliquely erect, shortly or obscurely  
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beaked, 18-20 mm high, 8-9 mm wide. Carpels: 5, elliptic-oblong. Follicles: 
contagious, linear-oblong, straight, 16-18 mm long. 
Seeds: pyramidal, 3-4 mm long, blackish brown.
[60] 
 
Chemical constituents 
Aconitum heterophyllum contains atidine, atisine, hetisine, heteratisine, 
Diterpene alkaloids like – heterophylline, heterophyllidine, heterophyllisine, 
hetidine. 
Tuber contains aconitic acid, tannic acid, pectin, ample starch, flat, oleic, palmitic 
and stearic glycerin mixture, vegetable mucilaginous matter, sucrose and ash 2 
percent. 
Root – The roots yield 0.79 per cent of total alkoloids. The following alkoloids 
are reported to have been isolated; Atisenol, Atsine, Heteratisine, Histisine, 
heterophyllisine, heterophylline, heterophyllidine, – atidine, Hetidine, 
Banzolheteratisine, F-dihydroatisine and Hetisinone. 
 
Traditional uses 
 Atees has been used from centuries to cure various diseases externally and 
internally as well. 
 Externally the crushed leaves and seeds are used to be applied on the throat to 
treat tonsillitis. 
 For Internal uses the juice of Atees roots along with milk is considered as an 
expectorant. The root powder of this plant is taken orally to cure cervical 
lymphadenitis. 
 The seeds and roots of Atees help in making digestive system strong. 
 Seeds are also thought to have diuretic properties which help in alleviating the 
burning sensation in urinary tract and increase the intensity of urine.
(12)
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Figure 4: Plant  Aconitum heterophyllum                    
 
Figure 5: Root Aconitum heterophyllum 
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3.   METHODOLOGY 
3.1 PLANT COLLECTION AND AUTHENTICATION 
         The root powder of the Aconitum heterophyllum was collected from Andhra 
Pradhesh and authenticated from Sri Venkateswara University, Tirupati. The 
authentication certificate number is No.     
3.2 EXTRACTION OF THE PLANT MATERIAL
[50] 
            The extraction is done by using Soxhlet apparatus. The coarse powder of the 
roots were first extracted with petroleum ether. Obtained defatted material is again 
extracted with chloroform. After extraction, the chloroform extract were evaporated or 
concentrated by using rotary evaporator and dried at room temperature to give a viscous 
mass. The obtained crude extracts were weighed and stored at 4
0
C for the further 
analysis. 
3.3 PHARMACOLOGICAL STUDY 
3.3.1 ANIMALS AND MANAGEMENT
[51] 
         Healthy adult Wistar albino rats of either sex weighing 180-250g will be selected. 
The animals will be housed in large, spacious, hygienic cages during the course of 
experimental period. The animal house will be well maintained and the animals will have 
12  1 hour day and night schedule with a temperature [64-79°F] maintained at standard 
experimental condition. The animals will be fed with standard rodent pellet feed and 
water ad libitum. The animals will be fasted 12 hours prior to the experiment with free 
access to only water.. The experimental procedure was approved by IAEC (Institutional 
animal ethical committee of KMCH, governed by CPCSEA, Government of India.  
3.3.2 ACUTE TOXICITY STUDY
[52] 
      Rats were kept overnight fasting prior to drug administration. A total of five animals 
were used which received a single oral dose (2000mg/kg) of chloroform extract of the 
root of Aconitum heterophyllum. After administration of the test extract, food was 
withheld further 3–4hr. Animals were observed individually at least once during the first  
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30min after dosing, periodically during the first 24hr (with special attention during the 
first 4hr) and daily thereafter for a period of 14days. Once daily, cage side observations 
included changes in skin and fur, eyes and mucous membrane (nasal) and also 
respiratory rate, circulatory (heart rate and blood pressure), autonomic (salivation, 
lacrimation, perspiration, piloerection, urinary incontinence, and defecation) and central 
nervous system (ptosis, drowsiness, gait, tremors and convulsion) changes. Mortality, if 
any, was determined over a period of 2 weeks. LD50 was done as per OECD guidelines 
for fixing the dose for biological evaluation . 
3.3.3 EVALUATION OF ANTIEPILEPTIC ACTIVITY OF CEAH 
A. Maximal electroshock seizure [MES] model
[28] 
Experimental design 
Wistar albino rats weighed around 150-250g were used for the study. Rats were divided 
into four groups of 5 animals each. 
Table-1: Maximal electroshock seizure model 
Model I: Maximal electroshock seizure [MES] Model 
Group 1: Vehicle control [Equivalent normal saline i.p] 
Group 2: Standard [Diphenylhydantoin 25 mg/Kg BW i.p] 
Group 3: Aconitum heterophyllum low dose ( 75 mg/kg) orally 
Group 4: Aconitum heterophyllum high dose (150 mg/kg) orally 
 
Procedure 
            Animals in the control group [Group 1] will be administered equivalent volume 
of normal saline by i.p route. Animals in Group 2 will be administered standard drug 
Diphenylhydantoin. In Groups 3 and 4 Aconitum heterophyllum low dose and high dose 
will be administered by oral route in 1% Sodium lauryl sulphate solution respectively.    
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After 30 minutes of administration of above drugs, all the rats will be given electroshock 
with electro convulsiometer through ear electrodes [after moistening the ear of animals 
with drop of normal saline] at intensity of 150 mA, 60Hz for 0.2 seconds. There after 
various parameters will be recorded.  
B. Pentylenetetrazol [PTZ] model
[28] 
Experimental design 
Wistar albino rats weighed around 150-250g were used for the study. Rats were divided 
into four groups of 5 animals each. 
Table-2: Pentylenetetrazole model 
Model II: Pentylenetetrazole Model 
Group 1: Vehicle control  [Equivalent normal saline i.p] 
Group 2: Standard Sodium valproate ( 150 mg/Kg BW i.p) 
Group 3: Aconitum heterophyllum low dose (75 mg/kg) orally 
Group 4: Aconitum heterophyllum high dose (150 mg/kg) orally 
 
Procedure 
             Animals in the control group [Group 1] will be administered equivalent volume 
of normal saline by i.p route . Animals in Group 2 will be administered standard drug 
Sodium Valproate. . In Groups 3 and 4 Aconitum heterophyllum low dose and high dose 
will be administered by oral route in 1% Sodium lauryl sulphate solution respectively. 
After 30 minutes of administration of above drugs, all the animals will be given 
Pentylenetetrazol [PTZ] and the various parameters will be recorded.  
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3.4 INVIVO ANTIOXIDANT STUDY 
Preparation of tissue homogenate: 
The animals were sacrificed after treatment by euthanasia. Brain was isolated and 
washed with normal saline and stored for in-vivo antioxidant studies. The separated brain   
weighing 0.5 gm were homogenized with motor driven Teflon coated homogenizer with 
5 mL of ice-cold 0.1 M Tris-HCl buffer pH 7.4 to get 10% homogenate. The homogenate 
was centrifuged at 10,000 rpm for 20 min at 5˚C. The supernatant was collected and used 
for the estimation and in-vivo antioxidant activity. 
3.4.1 ESTIMATION OF PROTEINS
[53] 
Reagents 
• Alkaline copper reagent 
• Solution A: 2% sodium carbonate in 0.1 N NaOH 
• Solution B: 0.5% copper sulphate in 1% sodium potassium tartarate 
• Solution C: 50 mL of solution A was mixed with 1 mL of solution B 
• Folin's phenol reagent (commercial reagent, 1:2 dilution) 
• Bovine serum albumin (BSA) 
Principle 
         This method is a combination of both Folin-ciocalteau and Biuret reaction which 
involves two steps. 
Step: 1 
Protein binds with copper in alkaline medium and reduces it to Cu++. 
Step: 2 
The Cu++ formed catalyses the oxidation reaction of aromatic amino acid by  
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reducing phosphor molybdotungstate to heteropolymolybdanum, which leads to the 
formation of blue colour and its absorbance was measured at 640 nm. 
Procedure 
            0.1 mL homogenate was made up to 1 mL with distilled water and to this; 5 mL 
of alkaline solution was added, mixed well and allowed to stand for 10 min. Then a 
volume of 0.5 mL Folin’s reagent was added, mixed well and incubated at room 
temperature for another 10 min. The blue color developed was measured at 660 nm 
against reagent blank. Bovine serum albumin (1 mg/mL) served as the standard and from 
the standard graph obtained; the amount of protein in the sample was calculated and 
expressed as mg/100 mg tissue. 
3.4.2 ENZYMATIC ANTIOXIDANT ACTIVITY 
Antioxidant Enzymes: 
            An antioxidant is any substance that when present in low concentration compared 
with those of an oxidizable substrate significantly delays or prevents oxidation of that 
substrate. The term ‘oxidizable substrate’ includes every type of molecule found in-vivo. 
The various antioxidant systems are Superoxide dismutases, Catalases, Glutathione 
peroxidase family and other peroxidases. 
3.4.2.1 ESTIMATION OF REDUCED GLUTATHIONE (GSH)
 [54] 
Principle: 
           DTNB (5, 5’-dithiobis (2-nitrobenzoic acid)), known as Ellman’s Reagent, was 
developed for the detection of thiol compounds. DTNB and glutathione (GSH) react to 
generate 2-nitro-5-thiobenzoic acid and glutathione disulfide (GSSG). Since 2-nitro-5-
thiobenzoic acid is a yellow colored product, GSH concentration in a sample solution 
can be determined by the measurement at 412 nm. 
Reagents 
 5% TCA 
 0.6 mM 5, 5’-dithiobis-2-nitrobenzoic acid (DTNB)  
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 0.2 M Phosphate buffer, pH 8.0 
Procedure 
          To 250 L of tissue homogenate taken in 2 ml eppendroff tube, 1 mL of 5% TCA 
was added and the above solution was centrifuged at 3000 g for 10 min at room 
temperature. To 250 L of the above supernatant, 1.5 ml of 0.2 M phosphate buffer was 
added and mixed well. 250 L of 0.6 mM of Ellman’s reagent (DTNB solution) was 
added to the above mixture and the absorbance was measured at 412 nm within 10 min. 
A standard graph was plotted using glutathione reduced solution (1 mg/mL) and GSH 
content present in the tissue homogenates was calculated by interpolation. Amount of 
glutathione expressed as g/mg protein. 
3.4.2.2 LIPID PEROXIDATION ASSAY
[55] 
 
Principle             
           Thiobarbituric Acid Reactive Substances (TBARS) is a well established assay for 
screening and monitoring lipid peroxidation. Lipid peroxides are unstable indicators of 
oxidative stress in cells that decompose to form more complex and reactive compounds 
such as malondialdehyde (MDA) which forms a 1:2 adduct with thiobarbituric acid.  
Procedure: 
           To 100 L of the tissue homogenate, 2 mL of (1:1:1 ratio) TBA-TCA-HCl 
reagent (TBA 0.37%, 0.25 N HCl and 15% TCA) was added and mixed. The above 
content was incubated in a boiling water bath for 15 min, cooled and centrifuged at 3500 
rpm for 10 min at room temperature. The pink colour developed was estimated at 535 
nm against a reagent blank, in a spectrophotometer. LPO was expressed as nmol of 
MDA/mg protein. 
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3.5 ESTIMATION OF BRAIN NEUROTRANSMITTER 
Preparation of brain tissue extracts
[56] 
            All groups were sacrificed, whole brain was dissected and separated the 
forebrain. Weighed quantity of tissue was homogenized in 5ml HCL- butanol for about 1 
min. The sample was then centrifuged for 10 min at 2000 rpm. An aliquot supernatant 
phase (1ml) was removed and added to centrifuge tube containing 2.5 ml heptane and 
0.31 ml HCL of 0.1 M. After 10 min of vigorous shaking, the tube was centrifuged under 
the same conditions as above inorder to separate the 2 phases, and the overlaying organic 
phase was discarded. The aqueous phase (0.2 ml) was taken for Gama-Aminobutyric 
acid (GABA), Glutamate (GLU), Serotonin (5-HT), Nor adrenaline (NA) and Dopamine 
(DA) assay. All steps were carried out at 0ºC.  
3.5.1 NOR ADRENALINE AND DOPAMINE ASSAY
[57] 
          To the 0.2 ml of aqueous phase, 0.05 ml 0.4 M HCL and 0.1 ml of sodium acetate 
buffer (pH 6.9) were added, followed by 0.1 ml iodine solution (0.1M in ethanol) for 
oxidation. The reaction was stopped  after 2 min by addition of 0.1 ml Na2SO3 solution. 
0.1 ml Acetic acid is added after 1.5 min. The solution was then heated to 100
º
C for 6 
min when the sample again reached room temperature, excitation and emission spectra 
were read from the spectroflourimeter. The readings were taken at 330-375 nm for 
dopamine and 395- 485 nm for nor adrenaline. 
3.5.2 SEROTONIN AND GLUTAMATE ASSAY
[58] 
          To 0.2 ml aqueous phase, 0.25 ml of OPT reagent was added. The fluorophore was 
developed by heating to 100ºC for 10 min. After the samples reached equilibrium with 
the ambient temperature, readings were taken at for serotonin 360- 470 nm and 
Glutamate 515 nm in the spectrofluorimeter. 
3.5.3 GABA ASSAY
[59] 
           A sample (0.1 ml) of tissue extract was placed in 0.2 ml of 0.14 M Ninhydrin 
solution in 0.5 M carbonate- bicarbonate buffer (pH 9.95) kept in a waterbath at 60ºC for 
30 min, then cooled and treated with 5 ml of copper tartarate reagent (0.16% disodium  
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carbonate, 0.03% copper sulphate and 0.0329% tartaric acid). After 10 min fluorescence 
at 377/455 nm in a spectroflourimeter was recorded. 
 
3.6 HISTOLOGICAL ASSESSMENT
[61] 
 Histopathology is the microscopical study of tissues for pathological alterations. 
This involves collection of morbid tissues from biopsy or necropsy, fixation, preparation 
of sections, staining and microscopical examination.
 
 Collection of materials 
 Thin pieces of 3 to 5 mm, thickness were collected from tissues showing gross morbid 
changes along with normal tissue. 
 Fixation: 
 Kept the tissue in fixative for 24-48 hours at room temperature 
The fixation was useful in the following ways: 
a) Serves to harden the tissues by coagulating the cell protein, 
b) Prevents autolysis, 
c) Preserves the structure of the tissue, and  
d) Prevents shrinkage  
Common Fixatives: 10% Formalin                             
 
Haematoxylin and eosin method of staining: 
 Deparaffine  the section by xylol 5 to 10 minutes and remove xylol by absolute alcohol. 
Then cleaned the section in tap water and stained with haematoxylin for 3-4 minutes and 
again cleaned under tap water. Allow the sections in tap water for few minutes and 
counter stained with 0.5% eosin until section appears light pink  (15 to 30seconds), and 
then washed in tap water. Blotted and dehydrated in alcohol and cleared with xylol  ( 15 
to 30 seconds). Mounted on a Canada balsam or DPX Moutant and kept the slide dry and 
remove air bubbles. 
 
3.7 STATISTICAL ANALYSIS 
            The datas of all the parameters were analyzed using the software Graph pad 
Prism 5. Analysis of variance (ANOVA); one way ANOVA followed by Dunnet's test 
was performed. The values were expressed as Mean ± SEM.  
Results 
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4.  RESULTS 
 
4.1 EXTRACTIVE YIELD OF EXTRACTS OF Aconitum heterophyllum 
Percentage Yield 
           The root powder of Aconitum heterophyllum were extracted with 
chloroform using soxhlet apparatus after deffating with petroleum ether. The 
percentage yield of extract was found to be 10 % w/w. 
 
4.2 ACUTE TOXICITY STUDY 
             The acute toxicity test was performed by using the chloroform extract at 
concentrations  2000 mg/kg, 1000 mg/kg, 900 mg/kg, 850 mg/kg, 800 mg/kg and 
750 mg/kg. As it is a natural substance and is not expected to be particularly 
toxic. Hence 2000 mg/kg of the test animal was administered orally. And 3 
animals were died. As mortality was observed after administration of 2gm/kg 
body weight, then a lower dose of 1000 mg/kg and 900 mg/kg was given. And 
mortality was observed for all animals for both doses. Hence a lower dose of 850 
mg/kg was given. Two animals died and one animal survived after administration 
of 850 mg/kg. Hence a lower dose of 800 mg/kg was given. Two animals 
survived and one animal died  for 800 mg/kg. Then a dose of 750 mg/kg was 
given. All animals survived for 750 mg/kg. and no signs of toxicity was observed 
following administration of 750 mg/kg. Hence Aconitum heterophyllum was 
found to be safe at 750 mg/kg. 
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Table-3: Acute toxicity study of Aconitum heterophyllum 
 
No. of animals used Dose (mg/kg) No.of animals survived 
3 2000 0 
3 1000 0 
3 900 0 
3 850 1 
3 800 2 
3 750 3 
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4.3 EVALUATION OF ANTIEPILEPTIC ACTIVITY 
Table-4: Effect of Chloroform extract of Aconitum heterophyllum on onset of hind 
limb extension in MES induced seizures models 
 
Statistical comparison: One way ANOVA, followed by Dunett’s multiple comparison 
test.  Standard, CEAH (low dose) and CEAH (High dose) are compared with control 
(p<0.05-
*
 , p<0.01
**
, p<0.001
***) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Groups             Onset  time (sec) Recovery/ 
Mortality 
Extension Clonus 
Control 3.40± 0.24 33.20± 1.15 Recovery 
Diphenylhydantoin 
(25mg/kg) 
17.00±0.31 * 0*** Recovery 
CEAH(75 mg/kg) 12.40± 0.50* 0*** Recovery 
CEAH(150mg/kg) 14.80± 0.37* 0*** Recovery 
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Figure-6: Effect of Chloroform extract of Aconitum heterophyllum on onset of hind 
limb extension in MES induced seizures models 
 
 
 
Statistical comparison: One way ANOVA, followed by Dunett’s multiple comparison 
test.  Standard, CEAH (low dose) and CEAH (High dose) are compared with control 
(p<0.05-
*
 , p<0.01
**
, p<0.001
***) 
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Table-5: Effect of Chloroform extract of Aconitum heterophyllum on MES induced 
seizures models 
 
Statistical comparison: One way ANOVA, followed by Dunett’s multiple comparison 
test.  Standard, CEAH (low dose) and CEAH (HIGH DOSE) are compared with control 
(p<0.05-
*
 , p<0.001
**
, p<0.0001
***)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Groups 
 
Flexion 
 
Extension 
 
Clonus 
 
Stupor 
Recovery/ 
Mortality 
Control  
5.60±0.4
 
 
18.6±0.5 
 
24±1.68 
 
50.40±1.77 
 
Recovery 
Diphenylhydantoin 
(25 mg/kg) 
 
2.20±0.20
*** 
 
4±1.04
*** 
 
0
*** 
 
11.00±0.44
*** 
 
Recovery 
CEAH (75 mg/kg)  
3.60±0.24
*** 
 
6±0.66
*** 
 
0
*** 
 
19.40±0.60
*** 
 
Recovery 
CEAH (150 mg/kg)  
2.80±0.20
*** 
 
5.4±1.50
*** 
 
0
*** 
 
14.40±0.67
*** 
 
Recovery 
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Figure-7: Effect of CEAH on duration of flexion after MES 
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Figure-8: Effect of CEAH on duration of extension after MES 
Extension
C
O
N
TR
O
L
D
YP
H
EN
Y
L 
H
Y
D
A
N
TO
IN
(2
5 
m
g/
kg
)
C
EA
H
(7
5 
m
g/
kg
)
C
EA
H
(1
50
 m
g/
kg
)
0
5
10
15
20
25
***
*** ***
D
u
ra
ti
o
n
 (
ti
m
e
/s
e
c
)
 
 
 
 
Results 
 
 
Department of Pharmacology                                                                                               Page 47 
 
Figure-9: Effect of CEAH on duration of stupor after MES 
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Statistical comparison: One way ANOVA, followed by Dunett’s multiple comparison 
test.  Standard, CEAH (low dose) and CEAH (HIGH DOSE) are compared with control 
(p<0.05-
*
 , p<0.001
**
, p<0.0001
***)
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Table-6: Effect of Chloroform extract of Aconitum heterophyllum on PTZ induced 
seizures models 
 
 
Statistical comparison: One way ANOVA, followed by Dunett’s multiple comparison 
test.  Standard, CEAH (low dose) and CEAH (HIGH DOSE) are compared with control 
(p<0.05-
*
 , p<0.001
**
, p<0.0001
***) 
 
 
 
 
 
 
 
 
 
 
 
 
Groups  Onset of 
convulsion (sec) 
Duration of 
convulsion (sec) 
Recover/ 
Mortality 
 
Control  
 
107.40 ±1.32 
 
74.00 ±1.41 
 
Mortality  
 
Sodium valproate(150mg/kg) 
 
680.60 ±1.28*** 
 
11.20 ±0.37*** 
 
Recovery  
 
CEAH (75 mg/kg) 
 
384.40 ±2.29*** 
 
27.40 ±0.67*** 
 
Mortatility  
 
CEAH (150 mg/kg) 
 
478.80 ±1.35*** 
 
45.80 ±0.73*** 
 
Recovery  
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Figure-10: Effect of Chloroform extract of Aconitum heterophyllum on onset of 
convulsion in PTZ induced seizure models 
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Figure-10: Effect of Chloroform extract of Aconitum heterophyllum on duration of 
convulsion in PTZ induced seizure models 
C
O
N
TR
O
L
S
O
D
IU
M
 V
A
LP
R
O
A
TE
(1
50
m
g/
kg
)
C
EA
H
(7
5m
g/
kg
)
C
EA
H
(1
50
m
g/
kg
)
0
20
40
60
80
D
u
ra
ti
o
n
 (
ti
m
e
/s
e
c
)
***
***
***
 
 
 
 
 
Results 
 
 
Department of Pharmacology                                                                                               Page 50 
 
4.4  INVIVO ANTIOXIDANT ACTIVITY 
  
 Table-7: Effect of CEAH on brain antioxidant GSH, Total protein, LPO in             
MES induced seizure models 
 
 
Statistical comparison: One way ANOVA, followed by Dunett’s multiple comparison 
test.  Standard, CEAH (low dose) and CEAH (high dose) are compared with control 
(p<0.05-
*
 , p<0.001
**
, p<0.0001
***)
 
 
 
 
 
 
 
 
 
 
 
 
Groups Total protein 
(mg/dl) 
GSH(mM/mg of 
tissue extract) 
LPO (nMoles of 
MDA released/ mg 
protein) 
Control 61.8± 0.80 35.2± 0.37 57.8± 0.42 
Diphenylhydantoin 
(25mg/kg) 
13.4 ±0.40*** 92.8± 0.33*** 14.2 ±0.37*** 
CEAH (75 mg/kg) 32.80 ±0.86
*** 73.8± 0.37*** 28.8± 0.33*** 
CEAH (150 mg/kg) 24.0± 0.44
*** 80.2± 0.80*** 23.8± 0.40*** 
Results 
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Table-8: Effect of CEAH on brain antioxidant GSH, Total protein, LPO in PTZ 
induced seizure model 
 
Statistical comparison: One way ANOVA, followed by Dunett’s multiple comparison 
test.  Standard, CEAH (low dose) and CEAH (HIGH DOSE) are compared with control 
(p<0.05-
*
 , p<0.001
**
, p<0.0001
***)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Groups Total protein 
(mg/dl) 
GSH (mM/ mg of 
tissue protein) 
LPO (nMoles of 
MDA released/ mg 
protein) 
Control 21.8± 0.33 98.0± 0.40 96.6± 0.40 
Sodium Valproate (150 
mg/kg) 
99.2± 0.37*** 42.4± 0.24*** 58.8± 0.58*** 
CEAH (75 mg/kg) 76.0± 0.44*** 57.0± 0.31*** 53.8± 0.37*** 
CEAH (150 mg/kg) 86.2± 0.37*** 52.0± 0.54*** 55.0± 0.31*** 
Results 
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Figure-12: Effect of CEAH on brain antioxidant GSH, Total protein, LPO in MES 
induced seizure models 
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Figure-12: Effect of CEAH on brain antioxidant GSH, Total protein, LPO in PTZ 
induced seizure model 
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4.5 EFFECT OF CEAH ON BRAIN NEUROTRANSMITTERS 
Table-9: Effect of CEAH on neurotransmitters levels in rat brain after MES 
induced epilepsy 
Groups  Nor 
adrenaline 
(µg/g tissue) 
Dopamine 
(µg/g tissue) 
Serotonin 
(µg/g tissue) 
GABA    
(µg/g tissue) 
Control  431.60±1.86 444.00±2.21 73.60±1.72 218.00±3.04 
Diphenylhydantoin 
(25mg/kg)     
584.20±1.35
*** 
741.20±2.55
*** 
136.80±1.65
*** 
292.80±2.22
*** 
CEAH(75mg/kg) 530.80±2.08
*** 
575.40±2.27
*** 
95.80±1.28
*** 
251.60±2.33
*** 
CEAH(150mg/kg) 545.60±2.58
*** 
645.60±2.06
*** 
114.60±1.77
*** 
271.20±1.88
*** 
 
Statistical comparison: One way ANOVA, followed by Dunett’s multiple comparison 
test.  Standard, CEAH (low dose) and CEAH (HIGH DOSE) are compared with control 
(p<0.05-
*
 , p<0.001
**
, p<0.0001
***)
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Table-10: Effect of CEAH on neurotransmitters level in rat brain after PTZ 
induced epilepsy 
 
Groups  Nor 
adrenaline 
(µg/g tissue)   
Dopamine 
(µg/g tissue) 
Serotonin 
(µg/g tissue) 
GABA    
(µg/g tissue) 
Control  524.00±1.51 212.80±2.08 93.00±1.78 205.40±1.07 
Diphenylhydantoin 
(25mg/kg)     
790.40±1.63
*** 
292.20±1.85
*** 
134.80±1.98
*** 
293.20±1.82
*** 
CEAH(75mg/kg) 682.80±1.93
*** 
252.80±2.51
*** 
112.20±1.98
*** 
254.00±1.41
*** 
CEAH(150mg/kg) 749.40±1.56
*** 
273.20±1.71
*** 
123.20±1.01
*** 
273.20±1.85
*** 
 
 
Statistical comparison: One way ANOVA, followed by Dunett’s multiple comparison 
test.  Standard, CEAH (low dose) and CEAH (HIGH DOSE) are compared with control 
(p<0.05-
*
 , p<0.001
**
, p<0.0001
***)
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Figure-14: Effect of CEAH on neurotransmitters levels in rat brain after MES 
induced epilepsy 
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Effect of CEAH on neurotransmitters levels in rat brain after MES induced 
epilepsy 
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Figure-15: Effect of CEAH on neurotransmitters level in rat brain after PTZ 
induced epilepsy 
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Effect of CEAH on neurotransmitters level in rat brain after PTZ induced epilepsy
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4.6 HISTOPATHOLOGICAL EVALUATION 
4.6.1 Histopathological evaluation of MES model 
 
Figure 16: Group 1: ONLY MES TREATED GROUP 
 
               
Normal hippocampus              Normal thalamus                Normal corpus striatum 
 
                                          
                      Normal substantia nigra                  cerebral cortex with neuronal loss 
 
 
From the results the rat brain shows normal hippocampus (dentate gyrus), thalamus, 
corpus striatum and substantia nigra and globus pallidus. Cerebral cortex shows neuronal 
loss. 
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Figure 17: Group 2: MES + Standard PHENYTOIN TREATED GROUP 
 
 
                                               
 
Degenerated hippocampus                                         Substantia nigra with edema 
 
 From the result rat brain shows hippocampus with degeneration, Substantia nigra shows 
with edema.  
 
 
 
Figure 18: Group 3:  MES + CEAH (75 mg/kg) TREATED GROUPS 
 
         
Hippocampus degeneration   Hippocampus sclerosis     cerebral cortex with edema 
 
From the results the rat brain shows hippocampus showing sclerosis and degeneration, 
cerebral cortex with edema.  
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Figure 19: Group 4: MES + CEAH (150 mg/kg) TREATED GROUP 
 
                                      
Hippocampus degeneration                                    Substantia nigra with edema 
 
 From the result rat brain shows hippocampus showing degeneration. Substantia nigra,  
shows neuronal loss with sclerosis. 
 
 
4.6.2. Histopathological evaluation of PTZ model 
 
Figure 20: Group 1: ONLY PTZ TREATED GROUP 
                                                                       
Normal cerebellum with                                               Cerebrum shows neuronal loss 
molecular purkinji cell layer 
 
                                     
Cerebral cortex shows edema                                      Cerebral cortex shows piknosis 
 From the result rat brain shows normal cerebellum with molecular purkinji layer. The 
cerebrum shows neuronal loss. Cerebral cortex shows edema and piknosis.  
Results 
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Figure 21: Group 2: PTZ + SODIUM VALPROATE TREATED GROUP 
                   
Cerebellum shows normal purkinji            Substantia nigra with edema 
cells with molecular layer 
 
From the result rat brain shows normal cerebellum shows normal purkinjiec cells with 
molecular layer and white matter. The substantia nigra shows neuronal loss and edema.  
 
 
Figure 22: Group 3: PTZ + CEAH (75 mg/kg) TREATED GROUP 
 
                     
 
Cerebellum with normal purkinji cells             Normal cerebral cortex 
and molecular layer 
 
 
From the result rat brain shows cerebellum with normal purkinjiec cells and molecular 
layer and white matter shows atrophy and gliosis. The cerebral cortex shows normal.  
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Figure 23:  PTZ + CEAH (150 mg/kg) TREATED GROUPS 
 
                   
Normal cerebellum shows purkinji cells       Cerebral cortex shows scelorosis 
 with molecular layer 
 
From the result rat brain shows normal cerebellum shows purkinji cells with molecular 
layer and white matter shows sclerosis and gliosis. The cerebral cortex shows sclerosis. 
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5. DISCUSSION 
Epilepsy is a chronic disorder of the brain that affect people worldwide. Nearly 
about 50-80% of the patients with epilepsy are controlled with currently available 
antiepileptic drugs. But these drugs cannot able to control seizures effectively in about 
10-20% of the patients. The treatment of epilepsy still remains inadequate even though 
new anticonvulsants are being developed. Furthermore the current therapy of epilepsy 
with modern antiepileptic drugs is associated with side effects, dose related and chronic 
toxicity as well as teratogenic effects.               
           Traditional systems of medicines are popular in developing countries and upto 
80% of the population relies on traditional medicines/ folk remedies for their primary 
health care need. Hence, there is a need to discover an alternative agent from natural 
sources.
[3] 
 Aconitum heterophyllum used as a herbal medicine and is well known for its 
traditional uses such as expectorants, diuretics, laxative etc. Various studies shows that 
the active principle diterpene alkaloids having a crucial role in treatment of epilepsy. 
Aconitum heterophyllum is rich in diterpene alkaloids.
[60]
 Since Aconitum heterophyllum 
have not been studied for its antiepileptic activity, the present study was aimed to 
evaluate the antiepileptic activity of chloroform extract of Aconitum heterophyllum 
The maximal electroshock induced convulsion in animals represents grand mal 
type of epilepsy. The tonic extensor phase is selectively abolished by the drugs effective 
in generalized tonic clonic seizure.
[19]
 The  result of the present study shows that the 
chloroform extract of Aconitum heterophyllum at doses 75 and 150 mg/kg significantly 
delayed the onset of HTLE and reduced the duration of HTLE. And also both doses 
completely abolished the phase of convulsion in MES induced convulsion models. 
In case of PTZ induced convulsion, the result of the present study shows that the 
chloroform extract of Aconitum heterophyllum , at doses 75 and 150 mg/kg significantly 
reduced the duration and also delayed the onset of convulsion when compared to control 
group. PTZ may be exerting convulsant effect by inhibiting the activity of GABA at 
GABAA receptors. The results revealed that the CEAH possess anticonvulsant activity.            
Oxidative stress was described as an imbalance between generation and 
elimination of reactive oxygen species and reactive nitrogen species. The brain is  
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particularly susceptible to oxidative stress because it utilizes the highest amount of 
oxygen than other body organs. It has been postulated that lipid peroxidation may be 
casually associated with certain types of epilepsy. A decrease in free radical scavenging 
activity may lead to an increased risk of seizure recurrence.
[61]
 The effect of CEAH on 
oxidative stress in MES and PTZ induced convulsion was evaluated. CEAH at doses 75 
and 150 mg/kg dose showed significant decrease in LPO level. 
          Glutathione reductase is an important free radical scavenging compound that 
prevents membrane lipid peroxidation. The decreased level of reduced glutathione in 
control group seen in the present study indicates that there was an increased generation 
of free radicals and that the reduced glutathione was depleted during process of 
combating oxidative stress.
[61]
 CEAH at doses 75 and 150 mg/kg dose showed significant 
increase in the GSH levels in brain tissue. The decrease in lipid peroxidation level and 
increase in the glutathione level in PTZ and MES induced convulsion models indicates 
that CEAH exhibit good antioxidant activity. 
 Epilepsy may develop because of an imbalance of nerve signaling chemicals 
called neurotransmitters. In case of epilepsy, there may be abnormally high level of 
excitatory neurotransmitters(glutamate) that increase neuronal activity, while abnormally 
low level of inhibitory neurotransmitters(GABA) that increase neuronal activity in the 
brain. Hence, GABA hypoactivity and glutamate hyperactivity can enhance an epileptic 
seizure. In epileptic foci, GABA hypoactivity, which reduces the activity of 
dopaminergic neurons through a presynaptic effect through GABAA receptors. At low 
doses, NA can enhance an epileptic seizures, whereas at high doses, it has a protective 
effect on seizures. Glutamate hyperactivity is exerted through presynaptic N- methyl- D- 
aspartate receptors, which strongly inhibit serotoninergic neurons and through post 
synaptic ionotropic glutaminergic receptors, which can induce epileptic seizures.
[15]
 The 
result of the present study shows that CEAH significantly increased  the level of 
inhibitory neurotransmitter GABA and  also showed significant increase in the levels of   
 DA, NA and 5-HT when compared to control group. The histopathological study shows 
alteration in neuronal activity in only MES and PTZ treated groups compared to 
standard, CEAH low dose and high dose. Hence, the result indicates that CEAH have 
good anticonvulsant activity. 
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6. CONCLUSION 
 
 Epilepsy is a neurological disorder that affects a wide range of people throughout 
the world. Approximately 30% of the patients continue to have seizures with current 
antiepileptic drug therapy. Natural products from folk remedies have contributed 
significantly in the discovery of modern drugs and can be an alternative source  for the 
discovery of antiepileptic drugs with novel structures and better safety and efficacy 
profiles.
[34] 
The chloroform extract of Aconitum heterophyllum delayed the onset and reduced 
the duration of convulsion in MES and PTZ induced convulsion models and can be used 
as an adjuvant therapy against cognitive deficit in convulsions. The extract also shows 
significant decrease in lipid peroxidation level and increase in reduced glutathione level, 
indicates that CEAH possess good antioxidant activity. Also CEAH significantly 
increased the level of inhibitory neurotransmitter GABA and also showed increase in 
DA, NA and 5-HT levels. Hence it can be concluded that the CEAH possesses  good 
anticonvulsant activity. Further studies are needed to explore the mechanism as well as 
the active principle responsible for the anticonvulsant activity of Aconitum 
heterophyllum. 
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